1. RAPAFLO® (silodosin) Capsules full Prescribing Information, Actavis Pharma Inc., October 2014.
  2. American Urological Association. AUA guideline on management of benign prostatic hyperplasia (2010).
  3. Andersson KE. Storage and voiding symptoms: pathophysiologic aspects. Urology. 2003;62(Suppl 5B):3-10.
  4. Scarpa RM. Lower urinary tract symptoms: what are the implications for the patients? Eur Urol. 2001;40(Suppl 4):12-20.
  5. Chartier-Kastler E, Tubaro A. The measurement of nocturia and its impact on quality of sleep and quality of life in LUTS/BPH. Eur Urol Supp. 2006;5:3-11.
  6. Peters TJ, Donovan JL, Kay HE, et al. The International Continence Society "Benign Prostatic Hyperplasia" study: the bothersomeness of urinary symptoms. J Urol. 1997;157(3):885-889.
  7. Bruskewitz RC. Quality of life and sexual function in patients with benign prostatic hyperplasia. Rev Urol. 2003;5(2):72-80.
  8. Hernández C, Estivill E, Prieto M, Badía X. Nocturia in Spanish patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH). Curr Med Res Opin. 2008;24(4):1033-1038.
  9. Roberts RO, Jacobsen SJ, Rhodes T, Girman CJ, Guess HA, Lieber MM. Natural history of prostatism: impaired health states in men with lower urinary tract symptoms. J Urol. 1997;157:1711-1717.
  10. Issa MM, Regan TS. Medical therapy for benign prostatic hyperplasia—present and future impact. Am J Manag Care. 2007;13(Suppl 1):S4-S9.
  11. Yokoyama O, Ito H, Aoki Y, Oyama N, Miwa Y, Akino H. Selective α1A-blocker improves bladder storage function in rats via suppression of C-fiber afferent activity. World J Urol. 2010;28:609-614.
  12. Komninos C, Mitsogiannis I. Obstruction-induced alterations within the urinary bladder and their role in the pathophysiology of lower urinary tract symptomatology. Can Urol Assoc J. 2014;8(7-8):e524-530.
  13. Schwinn DA, Roehrborn CG. α1-Adrenoceptor subtypes and lower urinary tract symptoms. Int J Urol. 2008;15:193-199.
  14. Carbone DJ, Hodges S. Medical therapy for benign prostatic hyperplasia: sexual dysfunction and impact on quality of life. Int J Impot Res. 2003;15:299-306.
  15. Yazaki J, Aikawa K, Shishido K, et al. Alpha1-adrenoceptor antagonists improve bladder storage function through reduction of afferent activity in rats with bladder outlet obstruction. Neurourol Urodyn. 2011;30(3):461-467.
  16. Cruz F, Desgrandchamps F. New concepts and pathophysiology of lower urinary tract symptoms in men. Eur Urol Supp. 2010;9(4):472-476.
  17. Nasu K, Moriyama N, Kawabe K, et al. Quantification and distribution of α1-adrenoceptor subtype mRNAs in human prostate: comparison of benign hypertrophied tissue and non-hypertrophied tissue. Br J Pharmacol. 1996;119(5):797-803.
  18. Murata S, Taniguchi T, Takahashi M, Okada K, Akiyama K, Muramatsu I. Tissue selectivity of KMD-3213, an α1-adrenoceptor antagonist, in human prostate and vasculature. J Urol. 2000;164(2):578-583.
  19. Townsend SA, Jung AS, Hoe YSG, et al. Critical role for the α-1B adrenergic receptor at the sympathetic neuroeffector junction. Hypertension. 2004;44(5):776-782.
  20. Data on file, Watson Laboratories, Inc.
  21. Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G. Rapid efficacy of the highly selective α1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol. 2009;181:2634-2640.
  22. Kobayashi K, Masumori N, Hisasue S, et al. Inhibition of seminal emission is the main cause of anejaculation induced by a new highly selective α1A-blocker in normal volunteers. J Sex Med. 2008;5(9):2185-2190.